FOR TRANSLATIONAL RESEARCH IN NUCLEAR MEDICINE
Arronax Nantes brings together all stakeholders in Nantes working on research and development in nuclear medicine.
This more particularly include the GIP ARRONAX, the laboratories Ceisam, CEMA-Oniris, CRCI2NA, LS2N, Subatech, the CRIP-Oniris core facility and the Nuclear Medicine departments of the University Hospital of Nantes and the ICO.
Arronax Nantes is a stakeholder in the I-SITE NExT, in close collaboration with the LabEx IRON and the SIRIC ILIAD.
our publications
Experimental cross-section measurement of the nuclear reactions induced by protons on 159Tb: Evaluation of the 155Dy/155Tb precursor system. Colucci M, Bolchini FC, Confalonieri L, Haddad F, Nigron E, Groppi F, et al. Radiation Physics and Chemistry. 1 nov 2024;224:112069.
https://doi.org/10.1016/j.radphyschem.2024.112069Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice, Roncali L, Marionneau-Lambot S, Roy C, Eychenne R, Gouard S, Avril S, et al., eBioMedicine [Internet]. 1 July 2024, https://doi.org/10.1016/j.ebiom.2024.105202
our news
ISI NucMed: end of the 3rd edition!
10/07/24
Valery Radchenko at GIP ARRONAX as part of the NExT – ICoN project
03/06/24
ARRONAX and Atonco sign contract to develop an innovative radiopharmaceutical
24/04/24
Vanessa targeting terbium production 155
29/02/24
Oncology: Arronax provides doses for an innovative clinical trial in alpha therapy
06/02/24
ISI NucMed 2024 : registration is now open!
06/02/24Our equipments
